Scholar Rock Corp (SRRK): Price-to-Revenue Ratio

Brandmark of Scholar Rock Corp (SRRK)

Scholar Rock is optimizing its resources by outsourcing production and testing to external partners, allowing the company to focus on developing unique antibodies to combat muscle atrophy. The price/sales multiple reflects the market valuation of the business, with this metric currently standing at 9236.50. Growth prospects depend on clinical trial results and a steady flow of R&D investment.

SRRK Scholar Rock P/S Multiple (07/04/2022 - 11/14/2026)

Metric breakdowns and analytics for scholarrock.com (SRRK)

- current quotes and average value forecast:
Market Price Scholar Rock, Inc.|SRRK - Price Target Chart
- stock exchange capitalization data:
Market Value Scholar Rock|SRRK - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Scholar Rock|SRRK - Book Capitalization|Market Value to Equity Ratio scholarrock.com|SRRK - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Scholar Rock|SRRK - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Scholar Rock|SRRK - Company Aggregate Debts|Debt to Book Value Scholar Rock Inc.|SRRK - Company Long-Term Debts|Company Short-Term Loans and Borrowings Scholar Rock|Immediate Liquidity scholarrock.com
- earnings and multiples data:
SRRK - Company Net Income|Expected Profit Scholar Rock|SRRK - P/E Multiple|Forward P/E Multiple Scholar Rock Inc.|SRRK - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Scholar Rock Holding Corporation|SRRK - Operating profit before deduction of amortization|Earnings per share for the trailing year Scholar Rock|SRRK - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months scholarrock.com|SRRK - Earnings per share growth in current year|Expected net earnings per share growth next year Scholar Rock
- issuer revenue and sales details:
SRRK - Revenue and Sales Volume|Company Future Sales Volume Scholar Rock, Inc.|SRRK - Price-to-Revenue Ratio|Forward P/S Multiple Scholar Rock
General company analysis:SRRK (Scholar Rock Holding Corporation)
Mass-produced product of Scholar Rock

The P/S multiple relates the market capitalization of Scholar Rock (SRRK) to its generated revenue, allowing for an assessment of the cost of each dollar of sales and the identification of the risk of overpaying for the asset. By analyzing the price-to-sales ratio, an investor can compare current market expectations with the company's high scientific potential in muscle atrophy therapy, determining the fair value of the biotech's future commercial successes.

Competing companies

JAZZ - Price to Sales|Price-to-Revenue Ratio Cytokinetics Inc CYTK|PTC Bio - Price-to-Revenue Ratio|CNTA - Price-to-Revenue Ratio|Price-to-Revenue Multiple Dyne Therapeutics (DYN)|EWTX: P/S Multiple|Price-to-Revenue Multiple Rapport Pharma RAPP|Market Cap to Revenue ALMS|Price to Sales Zevra Therapeutics ZVRA|P/S Multiple CTNM|Price-to-Revenue Ratio LRMR (Larimar Therapeutics)|P/S Multiple CAPR (Capricor Therapeutics Inc.)|TRDA: Market Cap to Revenue Ratio|Channel Therapeutics Inc. - P/S Multiple|MNOV (medicinova.com) - Market Cap to Revenue Ratio|Serina Therapeutics (SER) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio BTAI|Price-to-Revenue Ratio ProMIS Neurosciences, Inc.|Price to Sales Apimeds Pharmaceuticals APUS|P/S Multiple AEON|NLSP (NLS Pharmaceutics) - Market Capitalization-to-Revenue Ratio|P/S Multiple BNOX (bionomics.com.au)|P/S Multiple FSD Pharma, Inc. HUGE|Reata Pharmaceuticals, Inc. - P/S Multiple